APPLICATION
ANDA078932
TYPE
ANDA
ORIGINAL APPROVAL
2010-12-14
LATEST ACTION
2023-08-18
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription
Products
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 75MG BASE · TABLET · ORAL
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 37.5MG BASE · TABLET · ORAL
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 100MG BASE · TABLET · ORAL
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 50MG BASE · TABLET · ORAL
VENLAFAXINE HYDROCHLORIDEPrescription
VENLAFAXINE HYDROCHLORIDE EQ 25MG BASE · TABLET · ORAL
Approval history
2023-08-18Labeling · Supplement 27 · standardAP
2021-09-20Labeling · Supplement 26 · standardAP
2020-04-10Labeling · Supplement 14 · standardAP
2017-01-04Labeling · Supplement 9 · standardAP
2014-09-19Labeling · Supplement 6 · standardAP
2014-07-18Labeling · Supplement 5 · standardAP
2014-07-17Labeling · Supplement 4 · standardAP
2012-07-31Labeling · Supplement 3 · standardAP
2010-12-14OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.